НовостиBenzingaNeOnc Technologies Schedules FDA In-Person End-of-Phase 1 Type B Meeting Concerning NEO212 For November 17 NeOnc Technologies Schedules FDA In-Person End-of-Phase 1 Type B Meeting Concerning NEO212 For November 17 Benzinga 2026.09.28 12:06 (GMT+0) Открыть на Benzinga Другие новости